Literature DB >> 1666362

Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model.

E Bingen1, C Doit, N Lambert-Zechovsky, M Tod, O Petitjean, F Bourgeois, P Mariani-Kurkdjian.   

Abstract

A dynamic in vitro model was used to determine the killing kinetics of daptomycin against 15 vancomycin-resistant clinical isolates of Enterococcus faecium. Concentration profiles simulating those observed in serum following administration of both low-dose (2 mg/kg) and high-dose (6 mg/kg) daptomycin were bactericidal within 5.5 and 2.8 h, respectively. In contrast, when albumin was added to the growth medium, the corresponding bacterial killing times were slowed to greater than 24 h and 7 h; these results suggest that in the clinical setting, daptomycin dosages of approximately 6 mg/kg are required to achieve bactericidal activity against vancomycin-resistant Enterococcus faecium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666362     DOI: 10.1007/bf01984930

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

Review 1.  Antibiotic resistance in enterococci.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

2.  Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.

Authors:  N E Allen; J N Hobbs; W E Alborn
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Daptomycin (LY146032) treatment of experimental enterococcal endocarditis.

Authors:  L M Bush; J A Boscia; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

4.  Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.

Authors:  C W Stratton; L S Weeks
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

5.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

Authors:  S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

7.  Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.

Authors:  H F Chambers; J Mills; T A Drake; M A Sande
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec

8.  Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

Authors:  E Bingen; N Lambert-Zechovsky; R Leclercq; C Doit; P Mariani-Kurkdjian
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

9.  Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.

Authors:  M W Garrison; K Vance-Bryan; T A Larson; J P Toscano; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

10.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

View more
  5 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

Authors:  James H Jorgensen; Sharon A Crawford; Cynthia C Kelly; Jan E Patterson
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

4.  Killing kinetics of cefuroxime against Streptococcus pneumoniae in an in vitro model simulating serum concentration profiles after intramuscular administration.

Authors:  E Bingen; C Doit; R Farinotti; N Lambert-Zechovsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-04       Impact factor: 3.267

Review 5.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.